Literature DB >> 11111118

Comparative genomic hybridization study of de novo myeloid neoplasia.

M V Castuma1, P H Rao, S H Acevedo, I B Larripa.   

Abstract

Comparative genomic hybridization (CGH) was used to detect chromosomal imbalances in 20 patients with a diagnosis of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). The results obtained were compared with G-banding analysis. This last methodology showed 50% of cases with clonal abnormalities whereas CGH detected 70% of cases with copy number changes. Gains were more frequent than losses and constituted 66% of total changes detected. The most common gains included chromosomes 21 and chromosome region 18p for AML and chromosome 17 and region 1p33p35 for MDS. Losses represent 34% of changes and the regions involved were 5q31q32, 7q22, 7p12 and 13q21q22. CGH revealed additional chromosome imbalances in 12 of 20 cases (60%) which were not detected by traditional cytogenetic studies, demonstrating complex karyotype in 50% (6/12). Combination of CGH and G-banding provides an efficient method to identify critical regions present in the malignant clone, which is of great value in the prognosis and outcome of myeloid neoplasias. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2000        PMID: 11111118     DOI: 10.1159/000041065

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

1.  High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes.

Authors:  Christine L O'Keefe; Ramon Tiu; Lukasz P Gondek; Jennifer Powers; Karl S Theil; Matt Kalaycio; Alan Lichtin; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Exp Hematol       Date:  2007-02       Impact factor: 3.084

Review 2.  Whole genome scanning as a cytogenetic tool in hematologic malignancies.

Authors:  Jaroslaw P Maciejewski; Ghulam J Mufti
Journal:  Blood       Date:  2008-05-27       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.